AI Research
Jun 15, 2026
Startup Radical Numerics secures $50 million to advance AI in biology and drug discovery
Jun 15, 2026
AI Summary
Radical Numerics has raised $50 million in seed funding to develop AI models that can read, write, and reason about biological systems, including DNA and proteins. The company aims to address challenges in drug development and has formed partnerships for cancer detection and pathogen characterization.
- Eric Nguyen, a researcher with a background in AI and bioengineering, co-founded Radical Numerics after pursuing a PhD to find impactful problems in biology.
- The startup has secured $50 million in seed funding led by Emergence Capital, with participation from other investors including Obvious Ventures and Triatomic Capital.
- Radical Numerics focuses on creating AI models that understand various biological molecules simultaneously, building on previous work that led to the development of the first AI-generated functional virus.
- The AI drug discovery market is expected to grow significantly, with competitors like Ginkgo Bioworks entering partnerships to enhance their platforms.
- Unlike many AI biology companies that focus on single modalities, Radical Numerics aims to understand biological systems as a whole to overcome drug development bottlenecks.
- The company has established partnerships for cancer detection and pathogen characterization, with a revenue model that includes API licensing and proprietary models for pharmaceutical partners.
- Concerns exist regarding the potential misuse of AI in biological research, prompting the company to engage advisors with defense experience and reconsider open-source practices for future models.
- The vast majority of the human genome remains unexplored, and the company believes its technology could both advance understanding and provide safeguards against misuse.
aibiotechnologydrug discoverybiological systemsfunding